论文部分内容阅读
淋巴系统恶性肿瘤是常见的恶性血液病,目前治疗此类疾病的方法仍以干细胞移植及多疗程的化疗为主。治疗过程常出现不同程度的骨髓抑制,其中感染和出血为此类患者最常见的死因。成人中性粒细胞<0.5×109/L,称重度粒细胞减少症或粒细胞缺乏症,具有极高的感染风险。有报道聚乙二醇化重组人粒细胞集落刺激因子(PEG-rh G-CSF)预防肿瘤治疗后中性粒细胞减少的效果理想,但是尚无报道PEG-rh G-CSF用于治疗淋巴系统恶性肿瘤治
Lymphatic system malignancy is a common malignant blood disease, the current treatment of such diseases is still the method of stem cell transplantation and multi-course chemotherapy based. Myelosuppression is often seen in the course of treatment, with infection and bleeding the most common cause of death in these patients. Adult neutrophils <0.5 × 109 / L, severe neutropenia or agranulocytosis, with a high risk of infection. It has been reported that PEG-rhG-CSF is effective in preventing neutropenia after tumor therapy, but there is no report that PEG-rhG-CSF is used to treat malignant lymphatic system Cancer treatment